Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM)

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Healthcare & Pipeline Overview

Harrow Health, Inc., operating within the medical pharmaceutical sector, specializes in the development, production, and sale of innovative medications. With a focus on pharmaceutical compounding through its ImprimisRx business, Harrow serves a niche market, balancing growth initiatives with the complexities of pharmaceutical development and regulatory landscapes.

What Is the Investment Thesis for HROWM?

Harrow Health, Inc. presents a focused investment opportunity within the specialized pharmaceutical sector. With a market capitalization of $1.34B, the company's growth is tied to its ability to innovate and commercialize specialized medications. A gross margin of 75.1% indicates strong pricing power and efficient operations. However, a negative profit margin of -1.9% and a P/E ratio of -243.93 suggest challenges in achieving profitability. Key catalysts include successful drug development and expansion of the ImprimisRx business. Potential risks involve regulatory hurdles and competition from established pharmaceutical companies. Investors should monitor Harrow's progress in achieving profitability and expanding its market share in the specialized pharmaceutical market.

Based on FMP financials and quantitative analysis

HROWM Key Highlights

• Market Cap of $1.34B indicates Harrow's current valuation in the market.
• Gross Margin of 75.1% demonstrates strong pricing power and efficient production.
• P/E Ratio of -243.93 reflects current losses relative to its stock price.
• Profit Margin of -1.9% indicates that the company is currently operating at a loss.
• Beta of 0.14 suggests the stock is less volatile than the overall market.

Who Are HROWM's Competitors?

HROWM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HROWM's Key Strengths?

• Specialized product portfolio.
• High gross margin.
• Established ImprimisRx business.
• Focus on innovative medications.

What Are HROWM's Weaknesses?

• Negative profit margin.
• Reliance on specialized markets.
• Limited geographic reach.

What Could Drive HROWM Stock Higher?

• Clinical trial results for key drug candidates in the Pharmaceutical Drug Development segment.
• Expansion of the ImprimisRx business through new partnerships and product offerings.
• Regulatory approvals for new medications.
• Strategic acquisitions to expand the product portfolio.

What Are the Key Risks for HROWM?

• Negative return on equity (-33.7%) — the business is not currently generating profit on shareholder capital.
• Regulatory challenges and delays in drug approvals.
• Competition from larger pharmaceutical companies.
• Economic downturns affecting healthcare spending.
• Dependence on specialized markets.
• Risks associated with pharmaceutical compounding and product liability.

What Are the Growth Opportunities for HROWM?

• Expansion of ImprimisRx Business: Harrow can drive growth by expanding its ImprimisRx business, which focuses on pharmaceutical compounding. The market for personalized medications is growing as healthcare providers seek customized solutions for patients with unique needs. By increasing its compounding capabilities and expanding its network of pharmacies and healthcare providers, Harrow can capture a larger share of this market. The timeline for this growth opportunity is ongoing, with continuous efforts to enhance ImprimisRx's offerings and reach.
• New Drug Development: Harrow's Pharmaceutical Drug Development segment offers significant growth potential through the development and commercialization of new drugs. Successful clinical trials and regulatory approvals can lead to substantial revenue streams. The company's pipeline of drug candidates targets various therapeutic areas, addressing unmet medical needs. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review processes, with potential catalysts occurring in the next 2-5 years.
• Strategic Acquisitions: Harrow can pursue strategic acquisitions to expand its product portfolio and market reach. Acquiring complementary businesses or technologies can accelerate growth and enhance the company's competitive position. Potential acquisition targets include companies with specialized pharmaceutical products or compounding capabilities. The timeline for this growth opportunity is opportunistic, depending on the availability of suitable acquisition targets and the company's financial resources.
• Geographic Expansion: Harrow can expand its geographic presence by entering new markets. This can involve establishing partnerships with distributors or setting up operations in new regions. Expanding into international markets can provide access to a larger customer base and diversify revenue streams. The timeline for this growth opportunity is medium-term, with potential expansion efforts occurring over the next 3-5 years.
• Partnerships and Collaborations: Harrow can form partnerships and collaborations with other companies in the pharmaceutical industry to leverage their expertise and resources. Collaborations can involve joint development projects, licensing agreements, or co-marketing arrangements. These partnerships can accelerate drug development and commercialization efforts. The timeline for this growth opportunity is ongoing, with continuous efforts to identify and establish strategic partnerships.

What Opportunities Does HROWM Have?

• Expansion of ImprimisRx business.
• New drug development.
• Strategic acquisitions.
• Geographic expansion.

What Threats Does HROWM Face?

• Regulatory hurdles.
• Competition from established pharmaceutical companies.
• Economic downturns affecting healthcare spending.
• Patent expirations.

What Are HROWM's Competitive Advantages?

• Specialized product portfolio focusing on niche markets.
• Strong gross margin indicates pricing power.
• Established ImprimisRx business with a focus on pharmaceutical compounding.

What Does HROWM Do?

Harrow, Inc., founded in January 2006 by Mark L. Baum and Robert J. Kammer, is a healthcare company focused on developing, producing, and selling specialized pharmaceutical products. Headquartered in Nashville, TN, Harrow operates through two primary segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment is largely driven by the ImprimisRx business, which focuses on providing customized medications to meet specific patient needs. The Pharmaceutical Drug Development segment is dedicated to creating novel pharmaceutical products. Harrow's business model emphasizes innovation and addressing unmet needs in the pharmaceutical market. The company's products are distributed across the United States, targeting both individual patients and healthcare providers. Harrow's strategy involves a combination of organic growth and strategic acquisitions to expand its product portfolio and market reach. The company's focus on specialized medications differentiates it from larger pharmaceutical companies that concentrate on mass-market drugs.

What Products and Services Does HROWM Offer?

• Develops innovative medications.
• Produces specialized pharmaceutical products.
• Sells medications through its Pharmaceutical Compounding segment.
• Operates the ImprimisRx business, focusing on customized medications.
• Engages in Pharmaceutical Drug Development to create novel products.
• Distributes products across the United States.

How Does HROWM Make Money?

• Develops and manufactures specialized pharmaceutical products.
• Sells compounded medications through ImprimisRx.
• Generates revenue through product sales to healthcare providers and patients.

What Industry Does HROWM Operate In?

Harrow Health operates within the medical pharmaceutical industry, a sector characterized by intense competition, stringent regulatory requirements, and continuous innovation. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Harrow's focus on specialized medications positions it within a niche market, differentiating it from larger pharmaceutical companies. The company faces competition from both established players and smaller, specialized firms. The pharmaceutical industry is subject to regulatory oversight by agencies such as the FDA, which impacts drug development and commercialization processes.

Who Are HROWM's Key Customers?

• Individual patients requiring customized medications.
• Healthcare providers seeking specialized pharmaceutical products.
• Pharmacies that dispense compounded medications.

ROE -34%Key Financial Metrics

Return on equity for Harrow Health, Inc. 11.875% Senior Notes due 2027 stands at -33.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -3.6%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.1%, the inverse of the P/E and a quick read on earnings relative to price.

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Valuation Context

Valued at $1.34B, HROWM is classified as a small-cap stock.

Company Profile

Harrow Health, Inc. 11.875% Senior Notes due 2027 operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Nashville, US. The company is led by CEO Mark L. Baum. HROWM has traded publicly since 2022.

F-Score 6/9Financial Health

Harrow Health, Inc. 11.875% Senior Notes due 2027's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.08 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Harrow Health, Inc. 11.875% Senior Notes due 2027 revenue of about $398.0M for fiscal 2026, with EPS near $1.81.

HROWM Financials

HROWM Latest News

No recent news available for HROWM.

HROWM Analyst Consensus

HROWM MoonshotScore

Harrow Health, Inc. 11.875% Senior Notes due 2027 Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources